Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, confirmed by laboratory testing of tissue or cell samples
• People who have at least one tumour that can be measured using standard imaging guidelines
• People whose general health and ability to carry out daily activities falls within a certain range, rated as 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity only)
• People who are expected to survive for at least 12 weeks
• People whose blood counts, kidney function, and liver function meet the levels required by the trial
• People who have been fully informed about the study and have given their written agreement to take part
• (Phase 2 only) People from whom a tumour tissue sample can be provided — either from a stored sample taken before the screening period, or from a new biopsy taken during screening with the person's consent

Who may not be able to join:

• People who have had a severe allergic reaction to the study drug or to the other cancer medicines used in the trial
• People with a history of another type of cancer (other than pancreatic cancer)
• People who have had major surgery requiring general anaesthesia or breathing support
• People with serious heart conditions, including severe heart failure (classified as Class 3 or 4 on a standard heart health scale)
• People with a history of severe stroke or other serious brain blood vessel disease
• People with a history of blood clots in the lungs or legs, or serious lung conditions such as asthma or chronic obstructive pulmonary disease that are life-threatening
• People with an active infection currently being treated with antibiotics or antiviral medicines
• People with blood cancers
• People with large amounts of fluid build-up in the abdomen or around the lungs that requires draining
• People with significant nerve damage or numbness (Grade 2 or higher on a standard scale)
• People with ongoing diarrhoea or chronic inflammatory bowel disease
• People with bowel paralysis or bowel blockage
• People with conditions that make swallowing difficult or affect how the body absorbs medicines taken by mouth
• People with scarring or inflammation of the lungs (interstitial lung disease or pulmonary fibrosis)
• People currently on dialysis
• People with brain metastases (cancer that has spread to the brain) that are causing noticeable symptoms or are not well controlled
• People with uncontrolled high blood pressure (above certain measured levels)
• People with bleeding disorders
• People with active hepatitis B or hepatitis C infection
• People who are known to be HIV positive
• People who have previously received chemotherapy, biological therapy, or other anti-cancer drug treatments
• People who have received radiation therapy within 2 weeks before the start of the trial
• People who are currently taking, or are expected to need, certain medicines that strongly interact with a liver enzyme called CYP3A4 (confirm with trial site)
• (For one specific treatment group) People who are taking or expected to need a medicine called sorivudine
• People who need to regularly take anti-inflammatory painkillers (NSAIDs) that carry a high bleeding risk
• People who need ongoing steroid treatment at a dose above a certain level (equivalent to more than 10 mg per day of prednisone)
• People who are taking blood-thinning or anti-clotting medicines
• Women who are pregnant or breastfeeding
• Women who could become pregnant, and men, who are not willing to use appropriate contraception or abstain from sex during the study and for a set period afterwards (9 months for women, 6 months for men)
• People who have taken part in another clinical trial or used an investigational medical device within 4 weeks before the start of this trial
• People the trial doctor considers unsuitable or unable to participate for any other reason

Important: Always verify eligibility with the trial site directly before applying.